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allows the hydrolyzing of transmembrane domains of
integral membrane proteins. Presenilin contains two
aspartyl residues in its hydrophobic core that serve as
Els Marjaux, Dieter Hartmann,
and Bart De Strooper*
Laboratory for Neuronal Cell Biology
and Gene Transfer a catalytic site. Missense mutations of these residues
do not disturb the assembly of the -secretase complexCenter for Human Genetics, Vib4
K.U.Leuven, UZ Gasthuisberg but completely annihilate its proteolytic function (dis-
cussed in Nyabi et al., 2003). Some -secretase inhibi-Herestraat 49
3000 Leuven tors bind directly to presenilins, and recent experiments
show that structurally similar membrane bound prote-Belgium
ases can be found throughout the animal kingdom, pro-
viding circumstantial but convincing evidence that the
presenilins constitute a novel class of proteases. ThePresenilins are considered to be the catalytic subunits
of the -secretase complex and are therefore drug most relevant physiological substrates for the preseni-
lins are, without any doubt, the Notch proteins, largetargets for Alzheimer’s disease. They are also essen-
tial for the fine tuning of the immunological system and signaling receptors that are involved in a multitude of
developmental pathways. Notch signaling starts withfor memory and synaptic plasticity. Genetic ablation in
the forebrain results in a progressive neurodegenera- ligand binding followed by a conformational change in
the Notch ectodomain and proteolytic cleavages even-tive process that is independent from A generation.
The question arises as to what extent these observa- tually leading to the release of the Notch intracellular
domain by -secretase. In addition, presenilins/-secre-tions should influence our thinking on the pathogene-
sis of Alzheimer’s disease and on strategies to further tase cleave a number of other substrates, including
N- and E-cadherin, LRP, Syndecan, Delta, Jagged, CD44,develop -secretase inhibitors.
ErbB4, Nectin1, APP, and others (for an excellent re-
view, see Kopan and Ilagan, 2004). The evidence is
largely in vitro, and the physiological significance ofCurrent Alzheimer’s disease research focuses strongly
on the amyloid generating and clearing processes. these proteolytic processes remains unclear. One possi-
bility is that presenilins are responsible for the clearanceOne hopes that the removal of the amyloid plaques, e.g.,
by vaccination, will stop or prevent the further neuro- of transmembrane domains of proteins after they have
accomplished their mission, thus serving as the “protea-degenerative processes. Alternatively, inhibitors for ei-
ther - or presenilin/-secretase, the proteases that are some of the membrane” (Kopan and Ilagan, 2004). It is
also possible, however, that presenilins are “molecularresponsible for the cleavage of the amyloid peptide (A)
from the amyloid precursor protein (APP), could pre- switches” in many different signaling pathways.
The Presenilins and Notchvent the accumulation of the plaques. For all three ap-
proaches, serious concerns have been raised about One major way to gain an understanding of the biological
role of a protein is the genetic knockout approach inthe feasibility or potential side effects, but presenilin/
-secretase especially is a problem given its role in many whole organisms (Table 1). Studies in flies, worms, and
mice have all confirmed the crucial role of the presenilinscrucial physiological functions. Moreover, Jie Shen and
colleagues (Saura et al., 2004) demonstrated recently (PS) in Notch signaling. For instance, while inactivation
of PS1 in mice (Hartmann et al., 1999; Shen et al., 1997;that complete loss of presenilin (PS) function in the fore-
brain leads to memory loss, synaptic dysfunction, and Wong et al., 1997) yields a phenotype that features only
some aspects of deficient Notch-1 signaling (like dis-neurodegeneration—exactly what one aims to counter-
act in Alzheimer’s disease. These results also suggest turbed somitogenesis), additional ablation of its homo-
log PS2 (Donoviel et al., 1999; Herreman et al., 1999)that, at least in the familial forms of Alzheimer’s disease
caused by presenilin mutations, neurodegenerative pro- results in a presumably “full” Notch-1 phenotype. Ex-
cesses could be induced independently from abnormal pression of Notch-1 signaling target genes like Hes5 or
A generation and possibly contribute to the severity of Delta-like are altered in the mice (Handler et al., 2000;
the disease process in this subgroup of patients. Before Donoviel et al., 1999), confirming the deficiency at the
discussing the implications of the findings, some more molecular level. Recently published studies also shed
background information is needed. some light on the function of presenilin in adulthood.
The Presenilins PS1/PS2/-deficient mice (Tournoy et al., 2004;
The presenilins PS1 and PS2 most likely provide the Qyang et al., 2004) survive in apparent healthy condition
catalytic subunit of the large multiprotein complex called with only one PS1 allele until 6 months of age. They
-secretase (De Strooper, 2003). Together with the three display about 40% reduction in -secretase activity in
additional subunits (Nicastrin, Aph1, and Pen-2), they different organs. From 6 months on, however, sebor-
contribute a total of 18 hydrophobic transmembrane rheic karatosis and a spectacular autoimmune disorder
domains to the complex (Figure 1). These domains could develop with glomerulonephritis, vasculitis, and kerati-
create a microenvironment in the cell membrane that tis. The CD4/CD8 ratio of T lymphocytes is increased,
probably reflecting deficient Notch signaling, which is
critically involved in several differentiation steps of the*Correspondence: bart.destrooper@med.kuleuven.ac.be
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the lack of PS1 in adult brain. More importantly, the
results showed unequivocally the requirement of preseni-
lins for the normal function of the neuronal synapse.
Absence of presenilin expression in the neurons resulted
in decreased NMDA receptor levels in the synaptic mem-
brane and decreased CaMKII activity and altered
CREB/CBP gene regulation in the neuron, resulting in
impaired expression of c-fos and BDNF. The functional
consequences are dramatic, with strongly impaired LTP,
spatial and contextual memory deficits, and, after some
Figure 1. The Core of the -secretase Complex time, massive loss of synapses, dendrites, and neurons.
Remarkably, this neurodegeneration was accompanied
by increased Tau phosphorylation, likely via activationT lymphocyte lineage. Qyang et al. (2004) found in their
of CDK5/p25. These results challenge the quite simplecolony a myeloproliferative disorder dominating the
but preferred picture of the disease process in the famil-phenotype of the mice. Strain differences or environ-
ial forms of Alzheimer’s disease caused by presenilinmental factors could explain why the T cell lineage is
mutations. If these mutations cause partial loss of func-affected in one model and the granulocyte-monocyte
tion (for a discussion, see Saura et al., 2004, and Delineage is affected in another, but overall, the data dem-
Strooper, 2003), it is conceivable that, apart from theonstrate the essential functions of presenilins in different
effects on A generation, decreased Notch signalingaspects of white blood cell differentiation. Other interest-
and CREB/CBP activity could also contribute to the neu-ing mouse models have been generated using the Thy-1
rodegenerative process. This could explain why thesepromotor driving PS1 expression to rescue the lethal
patients display an earlier age of onset and a fasterdeficiency in PS1 knockout mice and resulting in more
progression rate than the patients with APP mutations.or less organ-specific knockouts. In (embryonic) kidney
A major question that needs further information is to(Wang et al., 2003), absence of PS1 and PS2 results in
what extent the synaptic changes are a consequencealtered nephrogenesis, likely because of deficient Notch
of the loss of -secretase function alone. Shen et al.signaling. In epidermis, loss of PS1 (Xia et al., 2001) results
(Saura et al., 2004) suggest that presenilins are neededin epidermal dysplasia and skin cancer. -catenin accu-
for the correct transport and insertion of the affectedmulation was proposed as the molecular cause of this
NMDA receptors in the postsynaptic membrane. Itdisease, but deficient Notch signaling could contribute
should be noticed that similar molecular trafficking func-to the phenotype as well (Nicolas et al., 2003).
tions for presenilins have been proposed in the pastOverall, it is clear that genetic deficiencies in preseni-
but that the supporting evidence remains quite indirect.lins affect a panoply of physiological functions, mainly
Decreased NMDA receptor signaling could explain thevia the Notch signaling pathway, but other pathways
decreased CaMKII activity and the changes in LTP andmight contribute as well.
synaptic transmission observed in the mice. AbnormalPresenilins and the Brain
Notch signaling could also contribute to the overall phe-
Given the central role of presenilins in Alzheimer’s dis-
notype: CBP contains a consensus sequence site for
ease, their function in the central nervous system is of
the CBF-1 (RBP-J) transcription factor, which is regu-
crucial interest. Selective inactivation of PS1 alone in the
lated by Notch (Saura et al., 2004). CBP is an essential
forebrain (FB-PS1KO) has been achieved by crossing cofactor for the transcription factor CREB and (genetic)
floxed PS1 gene mice (PS1cKO) with mice expressing deficiencies of these factors lead on their own to neuro-
Cre recombinase under the control of the CaMKII pro- degeneration (e.g., by decreased BDNF synthesis). Again,
motor (Feng et al., 2001; Yu et al., 2001). This results in this link needs further confirmation but illustrates a recur-
the specific postnatal inactivation of PS1 expression in rent theme in presenilin research, namely, the crucial con-
excitatory neurons of the cortex, hippocampus, and amyg- tribution of deficient Notch signaling to any phenotype
dala (Table 1). The mice appeared remarkably normal: observed until now in presenilin-deficient animals.
while they displayed a significant decrease in -secretase Implications for Our Thinking
activity (with accumulation of APP carboxy-terminal frag- on Alzheimer’s Disease
ments and decreased A generation), no overt anatomi- The work with the brain-specific presenilin knockout
cal or functional deficits could be demonstrated. Inter- mice makes clear how far away we still are from really
estingly, the expression of Notch downstream genes understanding the neurodegenerative mechanisms op-
(Hes 3 and 5, Delta-like 1) was not affected in the brains erating in Alzheimer’s disease. The question should be
of the FB-PS1KO mice. Only a discrete and mild impair- raised as to what extent the A amyloid peptide alone
ment in some memory tests was seen. The overall picture is capable of inducing the whole process and to what
emerging from these experiments seemed quite support- extent additional factors are necessary or additive to
ive for the concept of -secretase inhibitors. Apparently, the overall mechanism. The current publication (Saura
adult brain (or more specifically, the excitatory neurons et al., 2004) provides proof of the principle that, in familial
of the forebrain) can cope with decreased -secretase Alzheimer’s disease, both increased A42 and loss of
signaling, and the presence of PS2 is sufficient to main- function of presenilin could independently contribute
tain Notch signaling. Obviously, this remained to be in- to the pathogenesis. The discussion of whether A42
vestigated. Thus, FB-PS1KO mice were generated on a production reflects a “special gain” or a “partial loss”
PS2/ background (Saura et al., 2004). Strikingly, this of function (Saura et al., 2004; De Strooper, 2003) is
time a dramatic phenotype was observed, demonstra- hereby opened again, but the issue also needs further
exploration because it could shed light on some otherting that PS2 is indeed largely able to compensate for
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Table 1. Phenotypes in Partially or Fully Presenilin-Deficient Mice
Genotype Viability and Overall Phenotype Central Nervous System References
General KO
PS1/ lethal E17–P1; disturbed somitogenesis, underdeveloped ventricular 1, 2, 3, 4, 5, 6
skeleton abnormalities, angiogenesis zone, neuronal migration
deficits and hemorrhages, midline closure disorder (lissencephaly II)
defects
PS2/ normal; discrete lung fibrosis and — 7, 8
hemorrhages
PS1/PS2/ lethal E9.5; severe somite segmentation neural tube malformations 7, 8
defects, heart and second branchial arch
malformation, vascular defect in yolk sac
PS1/PS2/ autoimmune disease with glomerulonephritis, — 9, 10
keratitis, dermatitis, vasculitis, and
seborrheic hyperkeratosis myeloprolifera-
tive disorder
Tissue-specific KO
PS1cKO  CaMKII-Cre normal; (KO in forebrain: hippocampus, mild impairment of spatial 11, 12
(FB-PS1KO) amygdala, cortex) memory, subtle changes
in neurogenesis
PS1cKO  PS2/  CaMKII-Cre neurodegeneration with neuronal loss and severely impaired memory 13
(FB-PS1KO  PS2/) gliosis (KO in forebrain: hippocampus, and synaptic plasticity
amygdala, cortex) (from 2 months on),
synaptic loss, tau
hyperphosphorylation
PS1/  Thy1-PS1 skin cancer; hyperplasia, keratosis, and — 14
neoplasia (KO in skin)
PS1/PS2/  Thy1-PS1 lethal P1; nephrogenesis deficits (KO in kidney) — 15
1, Shen et al., 1997; 2, Wong et al., 1997; 3, Hartmann, et al., 1999; 4, Nakajima et al., 2003; 5, Takahashi et al., 2000; 6, Handler et al., 2000;
7, Donoviel et al., 1999; 8, Herreman et al., 1999; 9, Tournoy et al., 2004; 10, Qyang et al., 2004; 11, Yu et al., 2001; 12, Feng et al., 2001; 13,
Saura et al., 2004; 14, Xia et al., 2001; 15, Wang et al., 2003.
long-outstanding issues, such as why transgenic mice might affect the organism in a very different way than
the partial and changing modulation of its activity ob-with huge loads of A peptides in their brains do not
develop massive neurodegeneration and why in some tained by pharmacological intervention. For example,
genetic inactivation of Glycogen synthase kinase-3patients loads of A can be found in the brain without
overt signs of ongoing neurodegenerative processes. causes severe liver degeneration during embryogene-
sis, while LiCl, which inhibits this enzyme, is used for theOne possibility of reconciling the “amyloid hypothesis”
with the novel insights is to propose a “two hit” model treatment of manic depression. An even more striking
example is 3-hydroxy-3-methylglutaryl-co-enzyme Afor Alzheimer’s disease, in analogy with human cancer,
implying that A is a burden for the neurons but be- reductase (HMG-coA). Millions of people worldwide are
taking daily Statins to inhibit this enzyme, with the goalcomes only really toxic once the neurons are under
stress or are hit by additional insults. In the families of lowering their cardiovascular risk. Genetic ablation
of HMG-coA, however, results in an even more severewith presenilin mutations, the two hits (abnormal A42
generation and compromised synaptic function/neu- lethal phenotype than the one observed in PS knockout
mice: no embryos survive beyond the blastocyst stageronal survival) come from the same molecule; in other
forms of the disease, the second hit could be basically (Ohashi et al., 2003). Indeed, if the genetic experiments
had the final word about the drug programs, we wouldany event that weakens the neurons’ ability to cope with
stress. It still makes a lot of sense to try to block the never have had ACE inhibitors or Statins. Genetic experi-
ments are therefore great for understanding the biologi-production or increase the removal of A as a potential
treatment for (sporadic) Alzheimer’s disease, but impor- cal function of proteins, but their predictive value with
regard to the pharmacology is limited, and only in vivotantly, it also makes clear how important it is to focus
a bit more on this hypothetical second hit and to look toxicity tests and eventually clinical trials can decide
whether a drug has potential in the clinic or not. Further-for the contributing factors that set the stage for the
disease. The link from decreased synaptic activity to more, and in contrast to the genetic experiments, drug
treatment can be stopped, and problems can be re-decreased neuronal survival via the CREB/CBP signal-
ing pathway as outlined by Jie Shen and colleagues versed. Knowing the biological function of the target
allows, of course, a more directed monitoring of specific(Saura et al., 2004) could thereby become a central axis
for further fruitful research. problems, and for this aspect of drug development, the
information from basic research is certainly valuable.The End for Presenilins as Drug Targets?
The accumulating data on the many biological roles Finally, it should be pointed out that nobody aims to
block -secretase completely for the treatment of Alz-of presenilins obviously also have implications for our
thinking on -secretase as a viable drug target. Before heimer’s disease.
Opportunities for -secretase Inhibitor Researchmaking drastic decisions and putting aside presenilins/
-secretase, one should gain some distance. Indeed, The first issue to be considered when interpreting the
presenilin genetic knockout data (Table 1) in the contextthe genetic and usually complete deletion of a protein
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of drug development is that presenilins, in addition to extremely limited. We had better think twice before
dropping the presenilins from our drug target basket.their central role as catalytic subunits in the -secretase
complex, also potentially have other functions. They In conclusion, it is clear that the genetic studies on
presenilins have taught us that more research “out ofhave been implicated in -catenin turnover, in apoptosis
and Ca2 homeostasis, in protein transport, and in the the box” in the Alzheimer’s field is needed. We should
try to gain a much better understanding of which factorsassembly of the -secretase complex. While it is not al-
ways clear (e.g., for the regulation of Ca2) to what extent in the brain contribute to the toxicity of A and how this
leads to disease. This is required if we want to findthese functions are independent from their catalytic
-secretase activity, the possibility that non--secretase additional drug targets outside the strict boarders of
the “amyloid cascade hypothesis” and to increase ourfunctions of presenilins contribute to the overall PS
knockout phenotype has to be taken into account. Obvi- chances of finding cures for this terrible disease.
ously, inhibitors of -secretase will not necessarily affect
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